FDA Drug Recalls

Recalls / Class II

Class IID-0438-2022

Product

Lidocaine HCl / Oxymetazoline HCl Nasal Solution, 4% / 0.05%, 240mL per bottle, Multiple Dose Container for Intranasal Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1256-01, packaged in bottles. no label

Affected lot / code info
06-2021-18@3 12-15-2021 07/07/21 - 07/22/21 06-2021-30@10 12-27-2021 07/20/21 - 08/17/21 07-2021-14@4 01-10-2022 08/05/21 - 08/20/21 07-2021-21@4 01-17-2022 08/23/21 - 09/16/21, 07-2021-28@9 01-24-2022 09/13/21 - 10/05/21 08-2021-12@8 02-08-2022 10/01/21 - 10/19/21 08-2021-24@9 02-20-2022 10/19/21 - 11/11/21 09-2021-09@10 03-08-2022 11/10/21 - 11/30/21 10-2021-05@6 04-03-2022 11/30/21

Why it was recalled

CGMP Deviations

Recalling firm

Firm
Edge Pharma, LLC
Notification channel
Press Release
Type
Voluntary: Firm initiated
Address
856 Hercules Dr, Colchester, Vermont 05446-8014

Distribution

Quantity
386 bottles
Distribution pattern
nationwide

Timeline

Recall initiated
2021-12-06
FDA classified
2022-01-24
Posted by FDA
2022-02-02
Terminated
2023-06-07
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0438-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: drug · FDA Drug Recalls